PSMA-Directed Para-Aortic Radiation Therapy for Oligorecurrent Prostate Cancer

Inclusion Criteria

• •1. Histologically proven prostate adenocarcinoma
• •2. Male, ≥ 18 years old
• •3. Oligorecurrent disease limited to the sub-diaphragmatic region with or without pelvic lymph nodes
• •* a. No more than a total of 5 lesions on PSMA PET/CT scan (each lesion defined as positive with standardized uptake value (SUV) \> liver uptake and CT scan correlate)
• •* b. No disease outside of the pelvic and sub-diaphragmatic para-aortic lymph nodes
• •* c. At least one lesion in the sub-diaphragmatic para-aortic lymph nodes
• •* d. Non-bulky nodal disease (ie, tumor \<5 cm)
• •4. Prior pelvic radiation with disease response
• •* a. Definitive radiation therapy to the prostate with or without treatment of the pelvic lymph nodes and/or
• •* b. Salvage or adjuvant radiation therapy to the prostate bed following prostatectomy with or without treatment of the pelvic lymph nodes
• •5. Hormone-sensitive prostate cancer
• •6. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2
• •7. Ability to understand the investigational nature, potential risks and benefits of the research study, and willingness to sign the written informed consent and HIPAA document(s)
• •8. Willingness to fill out quality of life and psychosocial forms
• •9. Willingness to participate in our institution's Prostate Cancer Database Protocol (ID# 20090767)